Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 26 results
[ Author(Desc)] Title Type Year
Filters: Keyword is Crohn Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A.  2014.  Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.. Inflamm Bowel Dis. 20(6):1120-8.
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.  2017.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..  2017.  Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.
Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SGuk et al..  2007.  Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.. ISME J. 1(5):403-18.
C
Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A.  2019.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.
Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW.  2012.  Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.. PLoS One. 7(7):e41594.
D
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.  2015.  Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW.  2018.  Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..  2014.  Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
F
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
G
Ghosh G, Jacob V, Wan D.  2018.  Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.
Gold SL, Magro C, Scherl E.  2018.  A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.. Gastroenterology. 155(4):981-982.
K
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
L
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.  2020.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Lukin DJ.  2020.  Predictors of Perianal Fistula Relapse in Crohn's Disease.. Inflamm Bowel Dis. 26(6):932-933.
O
Otani T, Yamaguchi K, Scherl E, Du B, Tai H-H, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K et al..  2006.  Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.. Am J Physiol Gastrointest Liver Physiol. 290(2):G361-8.
P
Persley K, Scherl E, Rubin P.  2001.  Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis.. Am J Gastroenterol. 96(12):3444-5.
Q
Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R.  2019.  The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.. Inflamm Bowel Dis. 25(6):1044-1053.
S
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT.  2011.  Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.
V
Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al..  2017.  IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)
W
Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS.  2010.  Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.